Skip to main content

Table 2 Summary of studies in complicated intra-abdominal infection (cIAI)

From: Empiric therapy for hospital-acquired, Gram-negative complicated intra-abdominal infection and complicated urinary tract infections: a systematic literature review of current and emerging treatment options

  

CCR-TOCa

    

Index

Reference

Agent A

Agent B

Description

Quality high (H) or medium (M)

Comparative outcome (A vs B)

Year

A

[27]

Doripenem mITT 85.9 % (140/163)

Meropenem mITT 85.3 % (133/156)

R, DB, P3

H

Noninferior

2008

B

[28]

Tigecycline 86.1 % (441/512)

Imipenem-cilastatin 86.2 % (442/513)

Pooled analysis of two phase 3 trials.

H

Noninferior

2005

C

[29]

Tigecycline 92.4 % (219/237)

Imipenem-cilastatin 88.8 % (198/223)

Subanalysis of the European data from Study B

H

-

2008

D

[30]

Tigecycline 80.6 % (199/247)

Imipenem-cilastatin 82.4 % (210/255)

R, DB, P3

H

-

2005

E

[31]

Tigecycline mITT 86.5 % (45/52)

Imipenem-cilastatin mITT 97.9 % (47/48)

R, OL, P3

M

-

2010

F

[32]

Tigecycline 81.8 % (162/198)

Ceftriaxone-metronidazole 79.4 % (150/189)

R, OL

M

Noninferior

2012

G

[14]

Ertapenem 79.3 % (245/311)

Piperacillin-tazobactam 76.2 % (232/304)

R, DB, P3

H

Equivalent

2003

H

[33]

Piperacillin-tazobactam “Clinical success” 97.3 % (108/111)

Imipenem-cilastatin “Clinical success” 97.1 % (100/103)

R

M/H

-

2004

I

[34]

Piperacillin-tazobactam followed by amoxicillin clavulanate For HAI: 55 % (17/31)

Moxifloxacin For HAI: 82 % (22/27)

R, DB, P3

M

 

2006

J

[35]

Ceftolozane-tazobactam + metronidazole 91.4 % (64/70)

Meropenem 94.3 % (33/35)

R, DB, P2

M

-

2014

K

[36]

Ceftolozane-tazobactam 83.8 % (399/476)

Meropenem 85.8 % (424/494)

R, DB, P3

H

Noninferior

 

L

[37]

Ceftazidime-avibactam + metronidazole 91.2 % (62/68)

Meropenem 93.4 % (71/76)

R, P2

M

-

2013

  1. CCR-TOC clinical cure rate at the test-of-cure endpoint, DB double-blind, HAI hospital-acquired infection, MIC minimum inhibitory concentration, mITT microbiologically evaluable intent-to-treat population, OL open-label, P2 phase 2, P3 phase 3, R randomized.
  2. aUnless otherwise noted.